AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. ALNY
  4. [Form 4] Alnylam Pharmaceuticals, Inc. Insider Trading Activity

[Form 4] Alnylam Pharmaceuticals, Inc. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Kevin J. Fitzgerald, CSO & EVP, Head of Research at Alnylam Pharmaceuticals (ALNY), reported insider transactions tied to vested performance-based awards. On 08/15/2025 he was issued 2,851 shares following vesting of 30% of a performance-based stock unit granted 03/01/2024 after a clinical milestone determination. On 08/18/2025 he sold a total of 1,396 shares via multiple transactions under a mandatory sell-to-cover provision to satisfy tax withholding, at weighted sale prices ranging roughly between $447.53 and $456.00 per share. Following these transactions he beneficially owned 23,515 shares directly and an additional 537 shares indirectly through a managed account.

Kevin J. Fitzgerald, CSO e EVP, Responsabile della Ricerca di Alnylam Pharmaceuticals (ALNY), ha comunicato operazioni interne correlate a premi azionari basati su performance che sono maturati. Il 15/08/2025 gli sono state assegnate 2.851 azioni in seguito alla maturazione del 30% di una unit脿 azionaria di performance concessa il 01/03/2024 a seguito della determinazione di un traguardo clinico. Il 18/08/2025 ha venduto complessivamente 1.396 azioni in pi霉 transazioni nell'ambito di una disposizione obbligatoria di vendita per coprire le ritenute fiscali, a prezzi medi di vendita compresi approssimativamente tra $447,53 e $456,00 per azione. Dopo queste operazioni possedeva direttamente 23.515 azioni e indirettamente altre 537 azioni tramite un conto gestito.

Kevin J. Fitzgerald, CSO y EVP, Jefe de Investigaci贸n en Alnylam Pharmaceuticals (ALNY), inform贸 transacciones internas relacionadas con adjudicaciones de acciones basadas en desempe帽o que se hicieron efectivas. El 15/08/2025 se le emitieron 2.851 acciones tras la consolidaci贸n del 30% de una unidad accionaria por desempe帽o concedida el 01/03/2024 tras la determinaci贸n de un hito cl铆nico. El 18/08/2025 vendi贸 un total de 1.396 acciones en varias transacciones bajo una disposici贸n obligatoria de venta para cubrir retenciones fiscales, a precios medios de venta que oscilaron aproximadamente entre $447,53 y $456,00 por acci贸n. Tras estas operaciones pose铆a 23.515 acciones en propiedad directa y adem谩s 537 acciones indirectamente a trav茅s de una cuenta gestionada.

Kevin J. Fitzgerald, Alnylam Pharmaceuticals(ALNY) 鞐瓣惮齑濌磩(CSO) 瓴� 鞐瓣惮毂呾瀯鞛�(EVP), 電� 靹标臣 旮半皹 氤挫儊 靾橂牴鞐� 霐半ジ 雮措秬鞛� 瓯半灅毳� 氤搓碃頄堨姷雼堧嫟. 2025-08-15鞐� 鞛勳儊 靹标臣 韺愲嫧鞐� 霐半澕 2024-03-01鞐� 攵�鞐悳 靹标臣 旮半皹 欤检嫕 雼渼鞚� 30%臧� 頇曥爼霅橃柎 2,851欤缄皜 歆�旮夒悩鞐堨姷雼堧嫟. 2025-08-18鞐愲姅 靹戈笀 鞗愳矞歆曥垬毳� 於╇嫻頃橁赴 鞙勴暅 鞚橂鞝� 毵る弰 攴滌爼鞐� 霐半澕 鞐煬 瓯挫潣 瓯半灅搿� 齑� 1,396欤茧ゼ 毵る弰頄堨溂氅�, 欤茧嫻 臧�欷� 韽夑窢 毵り皝臧�電� 雽�霝� $447.53鞐愳劀 $456.00 靷澊鞓�鞀惦媹雼�. 鞚� 瓯半灅 鞚错泟 攴鸽姅 歆侅爲 23,515欤茧ゼ, 鞖挫毄 瓿勳毳� 韱淀暣 臧勳爲鞝侅溂搿� 537欤茧ゼ 氤挫湢頃橁碃 鞛堨棃鞀惦媹雼�.

Kevin J. Fitzgerald, CSO et EVP, Responsable de la Recherche chez Alnylam Pharmaceuticals (ALNY), a d茅clar茅 des op茅rations d'initi茅 li茅es 脿 des attributions d'actions bas茅es sur la performance qui sont arriv茅es 脿 茅ch茅ance. Le 15/08/2025, 2 851 actions lui ont 茅t茅 attribu茅es suite 脿 la consolidation de 30 % d'une unit茅 d'actions de performance accord茅e le 01/03/2024 apr猫s la validation d'un jalon clinique. Le 18/08/2025, il a vendu au total 1 396 actions au cours de plusieurs transactions dans le cadre d'une disposition obligatoire de vente pour couvrir les retenues fiscales, 脿 des prix de vente pond茅r茅s d'environ $447,53 脿 $456,00 par action. Apr猫s ces op茅rations, il d茅tenait directement 23 515 actions et indirectement 537 actions via un compte g茅r茅.

Kevin J. Fitzgerald, CSO & EVP, Leiter Forschung bei Alnylam Pharmaceuticals (ALNY), meldete Insidertransaktionen im Zusammenhang mit verfallenen leistungsbezogenen Aktienpr盲mien. Am 15.08.2025 wurden ihm 2.851 Aktien ausgegeben, nachdem 30 % einer am 01.03.2024 gew盲hrten leistungsabh盲ngigen Aktieneinheit nach Erreichen eines klinischen Meilensteins f盲llig geworden waren. Am 18.08.2025 verkaufte er insgesamt 1.396 Aktien in mehreren Transaktionen im Rahmen einer verpflichtenden Sell-to-Cover-Regel zur Begleichung der Steuerabz眉ge, zu gewichteten Verkaufspreisen von etwa $447,53 bis $456,00 je Aktie. Nach diesen Transaktionen hielt er direkt 23.515 Aktien sowie weitere 537 Aktien indirekt 眉ber ein verwaltetes Konto.

Positive
  • Performance milestone achieved: 2,851 shares issued upon vesting of 30% of a PSU after a clinical milestone determination on 08/15/2025
  • Significant continued ownership: Reporting person retains 23,515 shares directly and 537 shares indirectly, maintaining alignment with shareholders
Negative
  • Insider share sales: 1,396 shares sold on 08/18/2025 across multiple tranches at weighted prices roughly $447.53鈥�$456.00, reducing direct holdings
  • Tax-driven liquidity: Sales executed under mandatory sell-to-cover provision, indicating proceeds used for withholding obligations (reduces vested-share retention)

Insights

TL;DR: Insider received PSU shares after a clinical milestone and executed sell-to-cover transactions for tax obligations; activity appears administrative rather than a directional signal.

The reporting person was granted a performance-based stock unit that vested in part upon a clinical milestone, triggering issuance of 2,851 shares on 08/15/2025. The subsequent sales on 08/18/2025 (totaling 1,396 shares) were executed under a mandatory sell-to-cover provision, which is a routine mechanism to satisfy tax withholding on vesting events. The filings clearly disclose weighted-average price ranges for the multiple sale tranches and show continued meaningful ownership (23,515 direct shares plus 537 indirect). From a governance perspective, this is a common post-vesting liquidity action and is not, by itself, evidence of change in insider conviction.

TL;DR: The vesting reflects achievement of a corporate clinical milestone; sell-to-cover proceeds reduced share count modestly while leaving substantial insider ownership.

The 2,851-share issuance indicates a performance metric was met as of the committee determination on 08/15/2025. Sales on 08/18/2025 aggregated 1,396 shares across multiple price bands (weighted averages reported per tranche between approx. $447.53 and $456.00). Post-transactions direct beneficial ownership remained at 23,515 shares, with 537 shares held indirectly in a managed account, preserving insider alignment with shareholders. The pattern鈥攙esting followed by sell-to-cover鈥攁ligns with compensation tax mechanics rather than opportunistic cashing out.

Kevin J. Fitzgerald, CSO e EVP, Responsabile della Ricerca di Alnylam Pharmaceuticals (ALNY), ha comunicato operazioni interne correlate a premi azionari basati su performance che sono maturati. Il 15/08/2025 gli sono state assegnate 2.851 azioni in seguito alla maturazione del 30% di una unit脿 azionaria di performance concessa il 01/03/2024 a seguito della determinazione di un traguardo clinico. Il 18/08/2025 ha venduto complessivamente 1.396 azioni in pi霉 transazioni nell'ambito di una disposizione obbligatoria di vendita per coprire le ritenute fiscali, a prezzi medi di vendita compresi approssimativamente tra $447,53 e $456,00 per azione. Dopo queste operazioni possedeva direttamente 23.515 azioni e indirettamente altre 537 azioni tramite un conto gestito.

Kevin J. Fitzgerald, CSO y EVP, Jefe de Investigaci贸n en Alnylam Pharmaceuticals (ALNY), inform贸 transacciones internas relacionadas con adjudicaciones de acciones basadas en desempe帽o que se hicieron efectivas. El 15/08/2025 se le emitieron 2.851 acciones tras la consolidaci贸n del 30% de una unidad accionaria por desempe帽o concedida el 01/03/2024 tras la determinaci贸n de un hito cl铆nico. El 18/08/2025 vendi贸 un total de 1.396 acciones en varias transacciones bajo una disposici贸n obligatoria de venta para cubrir retenciones fiscales, a precios medios de venta que oscilaron aproximadamente entre $447,53 y $456,00 por acci贸n. Tras estas operaciones pose铆a 23.515 acciones en propiedad directa y adem谩s 537 acciones indirectamente a trav茅s de una cuenta gestionada.

Kevin J. Fitzgerald, Alnylam Pharmaceuticals(ALNY) 鞐瓣惮齑濌磩(CSO) 瓴� 鞐瓣惮毂呾瀯鞛�(EVP), 電� 靹标臣 旮半皹 氤挫儊 靾橂牴鞐� 霐半ジ 雮措秬鞛� 瓯半灅毳� 氤搓碃頄堨姷雼堧嫟. 2025-08-15鞐� 鞛勳儊 靹标臣 韺愲嫧鞐� 霐半澕 2024-03-01鞐� 攵�鞐悳 靹标臣 旮半皹 欤检嫕 雼渼鞚� 30%臧� 頇曥爼霅橃柎 2,851欤缄皜 歆�旮夒悩鞐堨姷雼堧嫟. 2025-08-18鞐愲姅 靹戈笀 鞗愳矞歆曥垬毳� 於╇嫻頃橁赴 鞙勴暅 鞚橂鞝� 毵る弰 攴滌爼鞐� 霐半澕 鞐煬 瓯挫潣 瓯半灅搿� 齑� 1,396欤茧ゼ 毵る弰頄堨溂氅�, 欤茧嫻 臧�欷� 韽夑窢 毵り皝臧�電� 雽�霝� $447.53鞐愳劀 $456.00 靷澊鞓�鞀惦媹雼�. 鞚� 瓯半灅 鞚错泟 攴鸽姅 歆侅爲 23,515欤茧ゼ, 鞖挫毄 瓿勳毳� 韱淀暣 臧勳爲鞝侅溂搿� 537欤茧ゼ 氤挫湢頃橁碃 鞛堨棃鞀惦媹雼�.

Kevin J. Fitzgerald, CSO et EVP, Responsable de la Recherche chez Alnylam Pharmaceuticals (ALNY), a d茅clar茅 des op茅rations d'initi茅 li茅es 脿 des attributions d'actions bas茅es sur la performance qui sont arriv茅es 脿 茅ch茅ance. Le 15/08/2025, 2 851 actions lui ont 茅t茅 attribu茅es suite 脿 la consolidation de 30 % d'une unit茅 d'actions de performance accord茅e le 01/03/2024 apr猫s la validation d'un jalon clinique. Le 18/08/2025, il a vendu au total 1 396 actions au cours de plusieurs transactions dans le cadre d'une disposition obligatoire de vente pour couvrir les retenues fiscales, 脿 des prix de vente pond茅r茅s d'environ $447,53 脿 $456,00 par action. Apr猫s ces op茅rations, il d茅tenait directement 23 515 actions et indirectement 537 actions via un compte g茅r茅.

Kevin J. Fitzgerald, CSO & EVP, Leiter Forschung bei Alnylam Pharmaceuticals (ALNY), meldete Insidertransaktionen im Zusammenhang mit verfallenen leistungsbezogenen Aktienpr盲mien. Am 15.08.2025 wurden ihm 2.851 Aktien ausgegeben, nachdem 30 % einer am 01.03.2024 gew盲hrten leistungsabh盲ngigen Aktieneinheit nach Erreichen eines klinischen Meilensteins f盲llig geworden waren. Am 18.08.2025 verkaufte er insgesamt 1.396 Aktien in mehreren Transaktionen im Rahmen einer verpflichtenden Sell-to-Cover-Regel zur Begleichung der Steuerabz眉ge, zu gewichteten Verkaufspreisen von etwa $447,53 bis $456,00 je Aktie. Nach diesen Transaktionen hielt er direkt 23.515 Aktien sowie weitere 537 Aktien indirekt 眉ber ein verwaltetes Konto.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Fitzgerald Kevin Joseph
(Last) (First) (Middle)
675 WEST KENDALL STREET
HENRI A. TERMEER SQUARE
(Street)
CAMBRIDGE MA 02142
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ALNYLAM PHARMACEUTICALS, INC. [ ALNY ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CSO & EVP, Head of Research
3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/15/2025 A(1) 2,851 A $0.0 24,115 D
Common Stock 08/18/2025 S(2) 39 D $447.98(3) 24,076 D
Common Stock 08/18/2025 S(2) 90 D $449.92(4) 23,986 D
Common Stock 08/18/2025 S(2) 39 D $450.92(5) 23,947 D
Common Stock 08/18/2025 S(2) 103 D $451.99(6) 23,844 D
Common Stock 08/18/2025 S(2) 329 D $452.96(7) 23,515 D
Common Stock 08/18/2025 S(2) 543 D $454.04(8) 22,972 D
Common Stock 08/18/2025 S(2) 241 D $454.84(9) 22,731 D
Common Stock 08/18/2025 S(2) 12 D $455.82(10) 22,719 D
Common Stock 537 I by Managed Account(11)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. On March 1, 2024, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of thirty (30) percent of the shares subject to the PSU based on the achievement of a clinical milestone, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on August 15, 2025.
2. Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024.
3. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $447.53 to $448.45. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
4. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $449.21 to $450.16. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
5. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $450.42 to $451.39. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
6. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $451.48 to $452.48. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
7. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $452.49 to $453.49. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
8. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $453.50 to $454.45. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
9. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $454.58 to $455.55. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
10. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $455.65 to $456.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
11. Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.
By: Brett Budzinski, Attorney-in-Fact For: Kevin Fitzgerald 08/19/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What insider transactions did Kevin Fitzgerald report for ALNY on Form 4?

He was issued 2,851 shares on 08/15/2025 upon vesting of 30% of a PSU and sold 1,396 shares on 08/18/2025 under a sell-to-cover provision.

Why were shares sold by the reporting person after vesting?

Sales were mandatory sell-to-cover transactions required to satisfy minimum statutory tax withholding obligations that became due upon vesting.

How many shares does Kevin Fitzgerald own after these transactions?

He beneficially owns 23,515 shares directly and 537 shares indirectly through a managed account following the reported transactions.

When was the PSU originally granted that led to the issuance?

The PSU was granted on March 1, 2024, with 30% vesting reported upon achievement of a clinical milestone.

What price range did the reported sales occur at?

Weighted-average sale prices for the tranches range approximately from $447.53 to $456.00, with specific tranche-weighted prices disclosed per sale in the filing.
Stock ALNY logo
Alnylam Pharmaceuticals Inc

NASDAQ:ALNY

ALNY Rankings

#255 Ranked by Market Cap
N/A Ranked by Dividends

ALNY Latest News

Aug 31, 2025
New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran鈥檚 Long-Term Cardiovascular Benefit in ATTR-CM
Aug 30, 2025
Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension
Aug 30, 2025
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial
Aug 27, 2025
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
Aug 11, 2025
Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025

ALNY Latest SEC Filings

Aug 29, 2025
[144] Alnylam Pharmaceuticals, Inc. SEC Filing
Aug 19, 2025
[Form 4] Alnylam Pharmaceuticals, Inc. Insider Trading Activity
Aug 19, 2025
[Form 4] Alnylam Pharmaceuticals, Inc. Insider Trading Activity
Aug 19, 2025
[Form 4] Alnylam Pharmaceuticals, Inc. Insider Trading Activity
Aug 19, 2025
[Form 4] Alnylam Pharmaceuticals, Inc. Insider Trading Activity

ALNY Stock Data

59.53B
125.76M
3.8%
99.09%
2.47%
Biotechnology
Pharmaceutical Preparations
United States
CAMBRIDGE